CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer

被引:51
作者
Benkheil, Mohammed [1 ]
Van Haele, Matthias [2 ]
Roskams, Tania [2 ]
Laporte, Manon [1 ]
Noppen, Sam [1 ]
Abbasi, Kayvan [1 ]
Delang, Leen [1 ]
Neyts, Johan [1 ]
Liekens, Sandra [1 ]
机构
[1] Univ Leuven KU Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, Leuven, Belgium
[2] Univ Leuven KU Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium
关键词
Chemokine; Angiogenesis; Hepatocellular carcinoma; Hepatitis C virus; LIGAND; 20; EXPRESSION; INFECTION; RECEPTOR; CELLS; ACTIVATION; PATHWAYS;
D O I
10.1016/j.yexcr.2018.09.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CCL20/CCR6 chemokine/receptor axis has previously been shown to contribute to the initiation and progression of hepatocellular carcinoma (HCC) through the recruitment of CCR6-positive leukocytes to the tumor microenvironment. In particular, high serum levels of CCL20 are reported in patients with HCC induced by the hepatitis C virus (HCV). A potential non-immune role for the CCL20/CCR6 axis in HCC development has not yet been investigated. Microarray analysis (Benkheil et al., paper submitted for publication), revealed that CCL20 is highly upregulated in hepatoma cells infected with HCV compared with non-infected hepatoma cells. To determine the role of the CCL20/CCR6 axis in HCV-related HCC, we first explored which cell populations express CCR6 in human liver tissue with chronic disease or HCC. Immunohistochemical (IHC) analysis revealed that CCR6 is present on endothelial cells (ECs) of portal blood vessels in livers with chronic HCV infection and in HCV- and alcoholic-HCC tissue. In addition, we found CCR6 to be expressed on primary macrovascular (HUVECs) and microvascular ECs (HMVEC-ds) where it co-expressed with the endothelial marker CD31. In vitro angiogenesis experiments revealed that CCL20 is a direct pro-angiogenic molecule that induces EC invasion, sprouting and migration through CCR6. Moreover, using the angiogenesis matrigel plug assay in immunodeficient NMRI-nu mice, we clearly showed that CCL20 induces blood vessel formation, by attracting CCR6-positive ECs. Finally, we demonstrated that HCV-induced CCL20 protein expression and secretion in hepatoma cells could be abolished by antiviral treatment, indicating that CCL20 expression is dependent on HCV replication. In contrast to HCV, HBV-infection resulted in a decreased expression of CCL20, implying a virus-specific effect. Taken together, we identified HCV-induced CCL20 as a direct pro-angiogenic factor that acts on endothelial CCR6. These results suggest that the CCL20/CCR6 axis contributes to hepatic angiogenesis, promoting the hypervascular state of HCV-HCC.
引用
收藏
页码:168 / 177
页数:10
相关论文
共 50 条
[21]   Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights [J].
Martin, Natasha K. ;
Thornton, Alicia ;
Hickman, Matthew ;
Sabin, Caroline ;
Nelson, Mark ;
Cooke, Graham S. ;
Martin, Thomas C. S. ;
Delpech, Valerie ;
Ruf, Murad ;
Price, Huw ;
Azad, Yusef ;
Thomson, Emma C. ;
Vickerman, Peter .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (09) :1072-1080
[22]   Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia [J].
Alavi, Maryam ;
Law, Matthew G. ;
Valerio, Heather ;
Grebely, Jason ;
Amin, Janaki ;
Hajarizadeh, Behzad ;
Selvey, Christine ;
George, Jacob ;
Dore, Gregory J. .
JOURNAL OF HEPATOLOGY, 2019, 71 (02) :281-288
[23]   Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease [J].
Honma, Yuichi ;
Shibata, Michihiko ;
Hayashi, Tsuguru ;
Kusanaga, Masashi ;
Ogino, Noriyoshi ;
Minami, Sota ;
Kumei, Shinsuke ;
Oe, Shinji ;
Miyagawa, Koichiro ;
Senju, Michio ;
Matsuoka, Hidehiko ;
Watanabe, Tatsuyuki ;
Hiura, Masaaki ;
Abe, Shintaro ;
Harada, Masaru .
LIVER INTERNATIONAL, 2019, 39 (09) :1641-1651
[24]   All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings [J].
Berenguer, Juan ;
Gil-Martin, Angela ;
Jarrin, Inmaculada ;
Moreno, Ana ;
Dominguez, Lourdes ;
Montes, Marisa ;
Aldamiz-Echevarria, Teresa ;
Tellez, Maria J. ;
Santos, Ignacio ;
Benitez, Laura ;
Sanz, Jose ;
Ryan, Pablo ;
Gaspar, Gabriel ;
Alvarez, Beatriz ;
Losa, Juan E. ;
Torres-Perea, Rafael ;
Barros, Carlos ;
San Martin, Juan V. ;
Arponen, Sari ;
de Guzman, Maria T. ;
Monsalvo, Raquel ;
Vegas, Ana ;
Garcia-Benayas, Maria T. ;
Serrano, Regino ;
Gotuzzo, Luis ;
Antonia Menendez, Maria ;
Belda, Luis M. ;
Malmierca, Eduardo ;
Calvo, Maria J. ;
Cruz-Martos, Encarnacion ;
Gonzalez-Garcia, Juan J. .
HEPATOLOGY, 2018, 68 (01) :32-47
[25]   Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs) [J].
Hassan, Waleed Attia ;
Kamel, Sherif I. ;
Mahmoud, Ibrahim Abdel Naby ;
Makhlouf, Nahed ;
Moubark, Mahmoud ;
Hassany, Sahar M. .
EGYPTIAN LIVER JOURNAL, 2023, 13 (01)
[26]   Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma [J].
Tanaka, Shogo ;
Shinkawa, Hiroji ;
Tamori, Akihiro ;
Takemura, Shigekazu ;
Uchida-Kobayashi, Sawako ;
Amano, Ryosuke ;
Kimura, Kenjiro ;
Ohira, Go ;
Nishio, Kohei ;
Tauchi, Jun ;
Kinoshita, Masahiko ;
Kawada, Norifumi ;
Kubo, Shoji .
HEPATOLOGY RESEARCH, 2021, 51 (11) :1102-1114
[27]   Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis [J].
Yuki Tahata ;
Hayato Hikita ;
Satoshi Mochida ;
Nobuyuki Enomoto ;
Norifumi Kawada ;
Masayuki Kurosaki ;
Akio Ido ;
Daiki Miki ;
Hitoshi Yoshiji ;
Yasuhiro Takikawa ;
Ryotaro Sakamori ;
Yoichi Hiasa ;
Kazuhiko Nakao ;
Naoya Kato ;
Yoshiyuki Ueno ;
Hiroshi Yatsuhashi ;
Yoshito Itoh ;
Ryosuke Tateishi ;
Goki Suda ;
Taro Takami ;
Yasunari Nakamoto ;
Yasuhiro Asahina ;
Kentaro Matsuura ;
Taro Yamashita ;
Tatsuya Kanto ;
Norio Akuta ;
Shuji Terai ;
Masahito Shimizu ;
Satoshi Sobue ;
Tomokatsu Miyaki ;
Akihiro Moriuchi ;
Ryoko Yamada ;
Takahiro Kodama ;
Tomohide Tatsumi ;
Tomomi Yamada ;
Tetsuo Takehara .
Journal of Gastroenterology, 2022, 57 :120-132
[28]   Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA) [J].
Niranjan-Azadi, Ashwini M. ;
Kabacam, Gokhan ;
Durand, Christine M. ;
Anjum, Saad ;
Saberi, Behnam ;
Dagher, Nabil N. ;
Philosophe, Benjamin ;
Gurakar, Ahmet .
ANNALS OF TRANSPLANTATION, 2017, 22 :570-574
[29]   Oral Direct-Acting Antiviral Therapy to Prevent Reinfection of the Liver Graft After Liver Transplantation for Hepatitis C Virus-Related Cirrhosis [J].
Kwo, Paul Y. ;
Tector, A. Joseph .
LIVER TRANSPLANTATION, 2013, 19 (07) :780-781
[30]   Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network ActivityLINA cohort) [J].
Gentile, Ivan ;
Scotto, Riccardo ;
Coppola, Carmine ;
Staiano, Laura ;
Amoruso, Daniela Caterina ;
De Simone, Teresa ;
Portunato, Federica ;
De Pascalis, Stefania ;
Martini, Salvatore ;
Macera, Margherita ;
Viceconte, Giulio ;
Tosone, Grazia ;
Buonomo, Antonio Riccardo ;
Borgia, Guglielmo ;
Coppola, Nicola .
HEPATOLOGY INTERNATIONAL, 2019, 13 (01) :66-74